US Patent 11,253,492 (Method for Increasing Dextromethorphan Half-Life with Bupropion): Claim Scope, Practical Coverage, and US Patent Landscape
Executive summary: US Patent 11,253,492 claims a targeted pharmacokinetic drug–drug interaction use: co-administering bupropion with dextromethorphan (DXM) in a non-poor DXM metabolizer, with defined dosing ranges (bupropion ~70–150 mg; DXM ~30–60 mg once or twice daily) for ≥8 consecutive days, to increase DXM elimination half-life on day 8 to at least 200% of DXM alone. Dependent claims narrow to longer treatment durations (≥14, ≥30 days), specific half-life bands (day 8 ~18–28 hours or ~20–28 hours), specific salt/formulation dosing (e.g., ~105 mg bupropion HCl with ~44–46 mg DXM HBr), and three therapeutic indication contexts (depression, nicotine addiction, Alzheimer’s agitation). The claim architecture is “interaction + phenotype + duration + quantified PK endpoint,” which constrains both design-around space and potential infringement theories. Patent risk for generics centers on whether any applicant markets or is studied under the claimed PK outcome using the claimed bupropion and DXM dosing regimens in non-poor metabolizers.
What does US 11,253,492 claim for increasing dextromethorphan elimination half-life with bupropion?
Direct claim focus (Claim 1): A method of increasing elimination half-life of dextromethorphan by co-administration with bupropion to a non-poor DXM metabolizer, with dose ranges, frequency, minimum treatment duration, and a quantified PK success criterion.
Key claim elements and how they bound infringement
-
Drug–drug pairing
- Bupropion + dextromethorphan must be co-administered.
- The claim does not require a particular formulation, but dependent claim 7 specifies particular salt-based amounts.
-
Patient phenotype requirement
- “Non-poor metabolizer of dextromethorphan.”
- This is a gating element. The claim is not written as “any human” but as a metabolizer-class-defined population. This limits infringement unless the study/labeling/prescribing practice fits the metabolizer definition.
-
Dosing ranges (daily) and dosing frequency
- Bupropion: about 70 mg to about 150 mg
- Dextromethorphan: about 30 mg to about 60 mg
- Administered once a day or twice a day
- The claim does not tie to a single fixed-dose product; it is dose-range-based.
-
Treatment duration
- At least 8 consecutive days is required to measure the endpoint “on day 8.”
- Dependent claims extend to ≥14 days and ≥30 days.
-
Quantified PK endpoint
- Elimination half-life of DXM “on day 8” must be:
- ≥ about 200% of the elimination half-life that would result when DXM is administered alone.
- This is a comparative endpoint. In practice, the method requires that DXM’s half-life increases relative to a baseline “DXM alone” comparator, within the same patient phenotype context.
What the “day 8, at least 200%” language implies for proof and enforcement
- The claim is written to require a measurement timing (day 8) and a relative magnitude (≥200% vs DXM alone).
- That structure tends to narrow enforcement to settings where a trial protocol or pharmacokinetic workup can demonstrate the threshold.
How do the dependent claims tighten scope in US 11,253,492?
Duration narrowers
- Claim 2: once/twice daily for ≥14 days
- Claim 3: once/twice daily for ≥30 days
These dependent claims create additional, narrower infringement hooks if a regimen is run longer than the base ≥8-day requirement.
Indication-specific dependent claims
Claims 4–6:
- Depression
- Nicotine addiction
- Agitation associated with Alzheimer’s disease
Claims 11–13 and 18–20 mirror these indication limitations, but in conjunction with the half-life band limitations (claims 8 and 15).
Implication: Indication-dependent claims can complicate infringement analysis when products are prescribed off-label or when studies do not tie to a claimed indication. If an applicant/marketing claim targets one of these indications with the claimed PK success, that is a clearer infringement posture.
Specific dose/salt embodiment (tight numeric content)
- Claim 7: about 105 mg bupropion hydrochloride (or molar equivalent salt/free base) co-administered with about 44–46 mg dextromethorphan hydrobromide (or molar equivalent salt/free base), once or twice daily.
This is the most operationally “formulation-anchoring” limitation in the set. It narrows the literal scope to a narrow numeric dosing window (for the particular salt forms).
Half-life numeric ranges
- Claim 8: day 8 elimination half-life ~18 to ~28 hours
- Claim 15: day 8 elimination half-life ~20 to ~28 hours
These create additional layers beyond the “≥200% vs DXM alone” comparator in Claim 1/22.
What is the maximum claim breadth on “non-poor metabolizers” and how does it affect infringement risk?
Non-poor DXM metabolizer is the central patient-phenotype limiting term. In infringement terms, it changes the question from “did you co-administer bupropion and DXM” to “did you co-administer them to a patient who qualifies as a non-poor metabolizer under the patent’s metabolizer definition.”
Because the independent and most dependent claims keep this phenotype element, any generic/brand challenge focusing on “any patient” may not map onto this patent if the phenotype gating is not met.
Operational consequence for R&D and licensing: A developer can reduce patent exposure by:
- studying or treating a phenotype that is not “non-poor” under the patent’s definition; and/or
- using regimens that do not achieve the claimed day 8 half-life increase relative to DXM alone.
The converse is that trials designed to demonstrate PK boosting in non-poor metabolizers create a direct path into Claim 1.
What is the structural difference between Claim 1 and Claims 22–28 (200% vs 300% threshold)?
- Claim 22 raises the endpoint magnitude:
- day 8 elimination half-life is ≥300% of DXM alone.
- Claims 23–28 are dependent on Claim 22 and mirror the duration, indication, and dosing/salt limitations found elsewhere.
Practical meaning:
- The patent landscape splits into a “baseline boosting” tier (Claim 1 at 200%) and a “stronger boosting” tier (Claim 22 at 300%).
- If a regimen reliably clears 200% but not 300%, it can still fall within Claim 1-type scope but avoid Claim 22.
Which bupropion and dextromethorphan dose regimens fall inside the numeric claim windows?
Literal dosing ranges (Claim 1/22 core)
- Bupropion: ~70–150 mg/day
- Dextromethorphan: ~30–60 mg/day
- Frequency: once daily or twice daily
- Duration: ≥8 days for measurement on day 8
Salt-anchored embodiment (Claim 7/14/21/28 style)
- ~105 mg bupropion HCl with ~44–46 mg DXM HBr once or twice daily
Half-life numeric ranges (Claims 8 and 15)
- Claim 8: ~18–28 hours
- Claim 15: ~20–28 hours
Because these are absolute half-life ranges (not solely percent increases), an infringer can design around by achieving boosting but keeping half-life outside the claimed band, or vice versa.
What therapeutic areas are explicitly covered and how does that interact with formulation and study design?
The claims explicitly mention:
- Depression
- Nicotine addiction
- Agitation associated with Alzheimer’s disease
Implication for patent landscape:
- If a company pursues DXM combinations with bupropion for these indications, the risk is highest when clinical protocols measure DXM PK on day 8 in non-poor metabolizers and demonstrate the claimed half-life increases.
Formulation interaction:
- Even if a product contains bupropion and DXM in different dosage-unit strengths, literal infringement can still occur as long as the administered daily amounts and the comparator endpoint are met. Dependent claim 7/14/21/28 adds the narrow salt embodiment, which can be avoided by using non-matching salt forms, but that is not a full design-around because Claim 1 is not limited to those salt forms.
How does the claim quantify “co-administering” and what dosing timing matters?
The claims use “co-administering… once a day or twice a day.” They do not add a specific inter-dose timing constraint (e.g., simultaneous administration) in the text provided.
Practical infringement angle:
- Co-dosing schedules that are consistent with once or twice daily administration can qualify.
- The core timing requirement is not relative timing between bupropion and DXM, but having the dosing regimen for at least 8 consecutive days and evaluating DXM elimination half-life on day 8.
What patent estate and US exclusivity hooks typically surround a PK-interaction method claim like 11,253,492?
Based on the claim content alone, the most relevant landscape artifacts are:
- any related US continuation-family members with overlapping “non-poor metabolizer + half-life endpoint on day 8” language,
- composition-of-matter or formulation patents for bupropion/DXM combination products that might be co-listed in Orange Book if an approved combination exists,
- method-of-treatment patents in the same therapeutic indications.
However, this response cannot enumerate other US patents in the family, claim numbers, expiration dates, assignees, or listing status in the Orange Book because those require external docket verification that is not included in the provided materials. Without those data, producing a “patent landscape” with specific patent numbers and litigation status would be incomplete.
What design-around strategies are suggested by the claim structure (scope management)?
Within the limits of the claim text provided, the highest-leverage design variables are:
-
Phenotype avoidance
- Avoid the “non-poor metabolizer” population as defined by the patent’s criteria (however defined in the specification).
-
Dose-range deviation
- Move bupropion and/or DXM outside:
- 70–150 mg bupropion/day
- 30–60 mg DXM/day
- or change frequency such that the administered daily total does not fall within the claimed range for the measurement window.
-
Duration manipulation
- If the only endpoint measurement occurs at day 8 under the protocol, then ensuring regimens do not sustain co-administration through the required consecutive days can avoid the “day 8” half-life requirement.
-
Endpoint magnitude and band targeting
- Achieve a half-life increase that is below 200% (avoid Claim 1).
- Or achieve 200% but keep day 8 half-life outside the absolute ranges in claims 8 and/or 15.
- Or achieve 200% but keep below 300% (avoid Claim 22/derivatives).
-
Indication and labeling strategy
- If an intended use is not within the three claimed indication contexts, that can reduce risk from indication-dependent claims (claims 4–6, 11–13, 18–20, 25–27).
How strong is infringement risk in practice for a generic or combination entrant?
Higher risk scenario
- A co-formulated or co-prescribed bupropion plus DXM regimen is studied or marketed for one of the three indicated therapeutic areas.
- The regimen uses daily doses falling within the specified ranges.
- Patients are classified as “non-poor DXM metabolizers.”
- The protocol includes PK measurement on day 8 and demonstrates DXM half-life increases of:
- ≥200% relative to DXM alone, or
- ≥300% relative to DXM alone (for the stronger tier).
Lower risk scenario
- The developer does not target the “non-poor metabolizer” group.
- Day 8 half-life is not increased past the percent threshold in the claim.
- Dosing stays outside the numeric ranges or the treatment period avoids the consecutive-day measurement anchor.
- The product is positioned for an indication not tied to the claim’s indication language.
Key Takeaways
- US 11,253,492 is a PK-success method claim: it requires a measured DXM elimination half-life on day 8 and a defined percent increase versus DXM alone.
- Claim scope is anchored by four constraints: non-poor metabolizer phenotype, co-administration of bupropion and DXM, dose ranges and dosing frequency, and the day 8 quantified endpoint.
- Dependent claims add longer durations, numeric half-life bands, salt-specific dosing, and three explicit therapeutic contexts.
- Design-around leverage is strongest on the phenotype constraint, the day-8 endpoint percent threshold (200% vs 300%), and whether day 8 half-life falls within the dependent absolute ranges.
- A full US landscape map (family patents, Orange Book listings, expiration dates, litigation, and challengers) requires external verification beyond the claim text supplied.
FAQs
-
What does “elimination half-life of dextromethorphan on day 8” mean for trial endpoints?
The protocol must support measuring DXM elimination half-life specifically at day 8, under the claimed co-administration regimen.
-
Can a product that uses different bupropion salts avoid the patent?
Claim 1 does not require bupropion HCl specifically; only dependent claim 7-style language ties to ~105 mg bupropion HCl paired with ~44–46 mg DXM HBr.
-
Does the patent cover both once-daily and twice-daily co-administration?
Yes. Claim 1 permits both once daily and twice daily, provided the dose ranges and consecutive-day duration conditions are met.
-
How do the 200% and 300% tiers change infringement exposure?
Claim 1 targets ≥200%; Claims 22 and its dependents target ≥300%. Regimens that clear 200% but not 300% can still fall within Claim 1 but avoid the stronger tier.
-
Do indication-specific dependent claims require FDA labeling to be infringed?
The claim language limits by therapeutic context. Infringement analysis turns on the actual claimed method use, not only label wording, but indication-dependent claim terms constrain the theory of use.
